First product to market
PL-Ex1
Placenta MSC-derived extracellular vesicles loaded with miR-124, developed as EviCure’s lead product program.
Lead program
PL-Ex1 targets solid cancers
The program is designed around therapeutic EV activity and targeted delivery, with an initial focus on refractory non-small-cell lung cancer.
PL-Ex1 targets multiple oncogenic pathways
Contact EviCure for additional development and program information.